Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 19376175)

1.

Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.

Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE.

Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37. doi: 10.1016/j.addr.2009.03.009. Epub 2009 Apr 17. Review.

2.

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE.

Mol Pharm. 2008 Jul-Aug;5(4):487-95. doi: 10.1021/mp800032f. Epub 2008 May 30. Review.

3.

Nanomagnetic sensing of blood plasma protein interactions with iron oxide nanoparticles: impact on macrophage uptake.

Lartigue L, Wilhelm C, Servais J, Factor C, Dencausse A, Bacri JC, Luciani N, Gazeau F.

ACS Nano. 2012 Mar 27;6(3):2665-78. doi: 10.1021/nn300060u. Epub 2012 Feb 16.

PMID:
22324868
4.

The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior.

Gao H, He Q.

Expert Opin Drug Deliv. 2014 Mar;11(3):409-20. doi: 10.1517/17425247.2014.877442. Epub 2014 Jan 8. Review.

PMID:
24397260
5.

Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration.

Semete B, Booysen L, Kalombo L, Ramalapa B, Hayeshi R, Swai HS.

Int J Pharm. 2012 Mar 15;424(1-2):115-20. doi: 10.1016/j.ijpharm.2011.12.043. Epub 2011 Dec 30.

PMID:
22227605
6.

Differential plasma protein binding to metal oxide nanoparticles.

Deng ZJ, Mortimer G, Schiller T, Musumeci A, Martin D, Minchin RF.

Nanotechnology. 2009 Nov 11;20(45):455101. doi: 10.1088/0957-4484/20/45/455101. Epub 2009 Oct 13.

PMID:
19822937
7.

Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems.

Karmali PP, Simberg D.

Expert Opin Drug Deliv. 2011 Mar;8(3):343-57. doi: 10.1517/17425247.2011.554818. Epub 2011 Feb 4. Review.

PMID:
21291354
8.

Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses.

Deng ZJ, Liang M, Toth I, Monteiro M, Minchin RF.

Nanotoxicology. 2013 May;7(3):314-22. doi: 10.3109/17435390.2012.655342. Epub 2012 Mar 6.

PMID:
22394123
9.

Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.

Li M, Panagi Z, Avgoustakis K, Reineke J.

Int J Nanomedicine. 2012;7:1345-56. doi: 10.2147/IJN.S23758. Epub 2012 Mar 7.

10.

Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts.

Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14265-70. doi: 10.1073/pnas.0805135105. Epub 2008 Sep 22.

11.

Dynamics of nanoparticle-protein corona complex formation: analytical results from population balance equations.

Darabi Sahneh F, Scoglio C, Riviere J.

PLoS One. 2013 May 31;8(5):e64690. doi: 10.1371/journal.pone.0064690. Print 2013.

12.

Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles.

Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, Dawson KA, Linse S.

Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5. Epub 2007 Jan 31.

13.

Serum heat inactivation affects protein corona composition and nanoparticle uptake.

Lesniak A, Campbell A, Monopoli MP, Lynch I, Salvati A, Dawson KA.

Biomaterials. 2010 Dec;31(36):9511-8. doi: 10.1016/j.biomaterials.2010.09.049.

PMID:
21059466
14.

Chitosan nanoparticle as protein delivery carrier--systematic examination of fabrication conditions for efficient loading and release.

Gan Q, Wang T.

Colloids Surf B Biointerfaces. 2007 Sep 1;59(1):24-34. Epub 2007 Apr 24.

PMID:
17555948
15.

Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines.

Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC.

Mol Pharm. 2012 Jan 1;9(1):81-90. doi: 10.1021/mp200264m. Epub 2011 Dec 16.

PMID:
22149016
16.

Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution.

Sarparanta M, Bimbo LM, Rytkönen J, Mäkilä E, Laaksonen TJ, Laaksonen P, Nyman M, Salonen J, Linder MB, Hirvonen J, Santos HA, Airaksinen AJ.

Mol Pharm. 2012 Mar 5;9(3):654-63. doi: 10.1021/mp200611d. Epub 2012 Feb 1.

PMID:
22277076
17.

Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size.

Zhang H, Burnum KE, Luna ML, Petritis BO, Kim JS, Qian WJ, Moore RJ, Heredia-Langner A, Webb-Robertson BJ, Thrall BD, Camp DG 2nd, Smith RD, Pounds JG, Liu T.

Proteomics. 2011 Dec;11(23):4569-77. doi: 10.1002/pmic.201100037. Epub 2011 Nov 4.

18.

Nanoparticle surface charge mediates the cellular receptors used by protein-nanoparticle complexes.

Fleischer CC, Payne CK.

J Phys Chem B. 2012 Aug 2;116(30):8901-7. doi: 10.1021/jp304630q. Epub 2012 Jul 20.

19.

The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers.

Stolnik S, Daudali B, Arien A, Whetstone J, Heald CR, Garnett MC, Davis SS, Illum L.

Biochim Biophys Acta. 2001 Oct 1;1514(2):261-79.

PMID:
11557026
20.

Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Alexis F, Pridgen E, Molnar LK, Farokhzad OC.

Mol Pharm. 2008 Jul-Aug;5(4):505-15. doi: 10.1021/mp800051m. Epub 2008 Aug 4. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk